Incruse Ellipta Shortage: What Providers and Prescribers Need to Know in 2026

This post is written for pulmonologists, primary care physicians, nurse practitioners, and physician assistants who prescribe Incruse Ellipta (umeclidinium 62.5 mcg) for COPD management. While no formal FDA shortage has been declared for this medication as of early 2026, intermittent localized availability gaps are affecting patient access. This update outlines the current landscape, clinical alternatives, and practical strategies to support your patients.

Current Availability Status

As of Q1 2026, Incruse Ellipta is not listed on the FDA's official drug shortage database. GlaxoSmithKline has not issued shortage notices to healthcare providers or wholesalers. However, localized stocking gaps are being reported by patients at the pharmacy level — particularly at chain pharmacies in lower-density markets and suburban areas. These gaps reflect demand-based stocking decisions rather than manufacturing disruptions.

Key context: Incruse Ellipta is the only brand-name umeclidinium monotherapy product in the U.S. It uses GSK's proprietary Ellipta dry powder inhaler. No generic is commercially available, and the earliest patent expiry window is December 2027. Pharmacies that see low local Incruse Ellipta volume may not maintain standing stock, leading to intermittent patient-reported unavailability.

Why Patients May Report Difficulty Filling Prescriptions

When a patient reports inability to fill their Incruse Ellipta prescription, consider these explanations before concluding there is a supply shortage:

• Pharmacy stocking gap: The pharmacy simply doesn't carry Incruse Ellipta regularly. Directing patients to independent pharmacies, specialty pharmacies, or mail-order options typically resolves this.
• Prior authorization expired or denied: Some payers require PA for Incruse Ellipta, especially on commercial formularies where it is Tier 3 or Tier 4. An expired or lapsed PA will block dispensing regardless of stock.
• Quantity limit reached: Some insurance plans impose quantity limits (e.g., one inhaler per 30 days). Early refill attempts will be denied.
• Cost barrier: Without insurance or adequate coverage, Incruse Ellipta retails for approximately $350–$415 per 30-day inhaler. Some patients may be declining to fill due to cost, not stock unavailability.

Clinically Appropriate Alternatives to Consider

If Incruse Ellipta remains unavailable for a patient despite exhausting pharmacy access options, the following LAMA alternatives are clinically appropriate for COPD maintenance:

• Tiotropium (Spiriva HandiHaler 18 mcg QD or Spiriva Respimat 2.5 mcg x2 puffs QD): Most prescribed LAMA in the U.S.; widely stocked; comparable efficacy. Clinical trials show umeclidinium had modestly greater trough FEV1 improvement (~53–59 mL) vs. tiotropium, but both are accepted first-line agents per GOLD guidelines.
• Aclidinium bromide (Tudorza Pressair 400 mcg BID): Twice-daily LAMA; similar anticholinergic profile. Twice-daily dosing may reduce adherence for some patients.
• Revefenacin (Yupelri 175 mcg QD via nebulizer): Appropriate for patients unable to use dry powder inhalers (low inspiratory flow, dexterity limitations). Requires access to a nebulizer.
• Upgrade to Anoro Ellipta (umeclidinium 62.5 mcg + vilanterol 25 mcg QD): Clinically appropriate if adding LABA therapy is warranted. Contains the same umeclidinium dose; uses the same Ellipta device. May be more reliably stocked given higher patient volumes.

Navigating Prior Authorization for Incruse Ellipta

Many commercial plans require prior authorization for Incruse Ellipta. Common PA criteria include documentation of a COPD diagnosis (with spirometry demonstrating post-bronchodilator FEV1/FVC < 0.70), failure or contraindication to first-line alternatives (often ipratropium or tiotropium), and a current inhaler technique assessment. Ensure PA requests include:

• Diagnosis code (J44.0, J44.1, or J44.9 as appropriate)
• Spirometry results confirming obstructive pattern
• Documentation of prior therapy (step therapy requirements, if any)
• Letter of medical necessity if step therapy requirements cannot be met

Patient Assistance and Savings Programs

For patients struggling with cost, two key programs are available from GSK:

• GSK "Pay No More Than $35" savings coupon: Available to commercially insured patients. Limits copay to $35 per fill for up to 12 fills. Applicable even if the patient has no insurance (for commercially available prescriptions). Call the GSK program at 888-825-5249.
• GSK For You Patient Assistance Program: Income-based assistance program for uninsured or underinsured patients. May provide Incruse Ellipta at no cost. Eligibility requirements apply; patients can enroll at gskkeytruda.com or by calling 866-728-4368.

How medfinder Can Support Your Patients

When patients encounter pharmacy availability issues, medfinder can help bridge the gap. medfinder calls pharmacies near the patient's location to identify which ones can fill their prescription, then delivers results by text — eliminating the burden of repeated pharmacy calls. Consider recommending medfinder to patients who report difficulty accessing Incruse Ellipta or other COPD inhalers. For provider-specific information on recommending medfinder to your patient panel, visit medfinder.com/providers.

Key Takeaways for Prescribers

• No FDA-declared shortage of Incruse Ellipta as of early 2026. Localized pharmacy stockouts are the primary issue.
• Prior authorization and insurance tier issues frequently masquerade as availability problems.
• Tiotropium (Spiriva) is the most clinically comparable and widely stocked LAMA alternative.
• GSK samples and copay assistance (down to $35/month) can bridge cost and access gaps.
• medfinder can help patients locate pharmacies with Incruse Ellipta in stock near them.